Sarepta Therapeutics | SRPT - Current Liabilities


Sarepta Therapeutics reported $1.1B in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 277.11M 79.47M Dec/2025
Agios Pharmaceuticals USD 82.21M 7.45M Dec/2025
Alnylam Pharmaceuticals USD 1.47B 89.13M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
BioCryst Pharmaceuticals USD 190.24M 13.08M Sep/2025
Biogen USD 3.35B 59.4M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Capricor Therapeutics USD 28.15M 249K Sep/2025
Daiichi Sankyo JPY 778.55B 77.51B Dec/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Esperion Therapeutics USD 359.03M 60.24M Sep/2025
Gilead Sciences USD 11.81B 485M Dec/2025
Incyte USD 1.52B 176.44M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Moderna USD 1.99B 306M Dec/2025
Nektar Therapeutics USD 66.34M 5.05M Sep/2025
Neurocrine Biosciences USD 743.4M 105.4M Dec/2025
Novavax USD 429.87M 40.73M Sep/2025
Pfizer USD 36.6B 1.13B Sep/2025
PTC Therapeutics USD 968.43M 102.18M Dec/2025
Regeneron Pharmaceuticals USD 4.37B 56.7M Dec/2025
Roche Holding CHF 28B 421M Dec/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Sanofi EUR 28.35B 3.76B Dec/2025
Sarepta Therapeutics USD 1.1B 173.86M Dec/2025
Tectonic Therapeutic USD 9.37M 1.99M Sep/2025
Ultragenyx Pharmaceutical USD 340.02M 46.78M Sep/2025
Vertex Pharmaceuticals USD 3.86B 614.1M Dec/2025